TC BioPharm (TCB) is an immunotherapy company developing novel cell based products for treatment of cancer and severe viral infections. TCB employs a team of over 40 staff and acts as a fully integrated pharmaceutical company encompassing GMP Manufacture, quality, product development, regulatory affairs and in-house clinical research.

Management Team

Dr Michael Leek

Chief Executive & Founder

Michael has 27 years’ experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture, clinical, regulatory and logistic expertise, he has directly raised over £50m in equity and grant funding.

Dr Artin Moussavi

Chief Business Officer, Chairman & Co-Founder

Artin has founded successful companies in biotech, medical and energy industries and built an international nutrition business; achieving over £5m sales in the first year. He was the winner of Pfizer’s Award for Innovation in life sciences (2006), sourced and prepared multi-million venture capital investments for a global life sciences fund (Inventages).

Angela Scott

Chief Operating Officer & Co-Founder

Angela has 32 years in oncology research and regenerative medicine, was part of the team that cloned ‘Dolly the Sheep’, and has designed, built and commissioned several GMP manufacturing facilities. She manufactured product for the UK’s ‘first-in-man’ stem cell trial (PISCES – ReNeuron), and has held MHRA -MIA and -IMP licenses for several cell therapy products.

David Gallagher

Vice President - Commercial & Co-Founder

A qualified lawyer, David has more than a decade of experience in advising companies, from SMEs to large listed companies, particularly in relation to Intellectual Property and commercialisation. David has advised start-ups, large scale manufacturing companies, Contract Research Organisations, funders and venture capitalists on a range of issues including patent protection strategy, distribution and licensing arrangements, negotiation of cross border commercial contracts, manufacturing and regulatory issues.

Dorothy Lister

Vice President - Operations

Dorothy has 31 years’ experience within contract research and manufacturing organisations and has been responsible for the project and supply chain management of large complex packaging and distribution activities in support of worldwide clinical trials for two global healthcare companies. In her previous role, Dorothy was also one of the first employees taken on to manage technical transfer for a large US CRO establishing a new European GMP testing facility in Scotland. Her operations experience has also extended to the design, build and project management of several GMP facilities and has been involved in many successful MHRA audits.

Dr Tomasz Zaremba

Vice President - Clinical

Tomasz has a PhD in Cancer Research from Newcastle University and an MBA. He also has extensive experience running international phase I-IV clinical trials (ovarian, breast, thyroid prostate and lung cancer) gained whilst at AstraZeneca.

Toby Rintoul

Vice President - Finance

Toby is an experienced business adviser to a range of fast growing and entrepreneurial companies. Leading the business solutions team at Johnston Carmichael, he specialises in advising fast growing clients in a number of sectors from SME’s to publicly traded companies with a particular focus on technology and life science companies.

Board of Directors

Dr Michael Leek

Chief Executive & Founder

Michael has 27 years’ experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture, clinical, regulatory and logistic expertise, he has directly raised over £50m in equity and grant funding.

Dr Artin Moussavi

Chief Business Officer, Chairman & Co-Founder

Artin has founded successful companies in biotech, medical and energy industries and built an international nutrition business; achieving over £5m sales in the first year. He was the winner of Pfizer’s Award for Innovation in life sciences (2006), sourced and prepared multi-million venture capital investments for a global life sciences fund (Inventages).

Kazuyuki Takeda

NIPRO representative

Takeda-san has been a member of Nipro Corporation for over 20 years and is the General Manager of Nipro’s Cell Product Sales and Development Division.  A graduate of Kobe Gakuin University Faculty of Law, he is also a Director of Cell Science & Technology Institute Inc., a Nipro subsidiary.

Hajime Miyamoto

MEDINET Representative

Miyamoto-san is a member of the Board and Head of Administration Division of Medinet Co., Ltd., a company processing immuno-cells for medical institutions who provide cell therapy. Before he joined Medinet, he spent 24 years at Fujitsu Ltd. in the area of software, legal and policy promotion. Last year, he was appointed as the Vice Chairman of the Steering Committee of FIRM (Forum for Innovative Regenerative Medicine).

Dr Alan Clark

Scottish Enterprise Representative

Alan has significant experience in the biotech and pharmaceutical industries with a strong track record in R&D strategy, commercial evaluation and licensing. Alan has held roles in pharmaceuticals with Organon (now Merck) and Alere Inc. In 2007, Alan founded Theraldia Consulting and since then has worked with a large number of global clients including SMEs, investors, and large pharma. His roles have spanned across many therapeutic areas including infectious disease and cancer. Alan holds a BSc in Biochemistry from Heriot-Watt University and a PhD in Neuroscience from the University of Edinburgh.

Lorraine Porter

Investing Women Representative

Lorraine was a director and co-founder of STATS Group, a £40 million turnover engineering design and manufacture business in the oil and gas sector based in Aberdeenshire.  Since leaving her full time role she has spent her time advising, mentoring and bringing over 30 years expertise to several start-up businesses. She is an active angel investor and member of Investing Women.

Martin Thorp

NCL Innovation Representative

Martin is Director of Capital Markets of NCL Innovation, a UK based corporate finance and equity investment firm, focused on supporting disruptive technologies through pre and early stage commercialisation.

Research Partners

Beatson West of Scotland Cancer Centre

The Beatson, which rivals Europe’s top cancer hospitals in terms of facilities and equipment, provides West of Scotland cancer patients and staff with the most cutting edge equipment, treatments and surroundings to fight cancer.

Completing the world-class package of cancer care, the new Beatson is staffed by some of the most skilled and dedicated healthcare professionals in the country.

Edinburgh Cancer Centre, Western General Hospital

The Edinburgh Cancer Center is located in the Western General Hospital.

Cancer Research UK, Oxford Centre

Established in 2010, the CRUK Oxford Centre (formerly the Oxford Cancer Research Centre) is a network and partnership between Oxford University, Oxford University Hospitals NHS Trust and Cancer Research UK, based on the University’s Translational Biomedical Research Campus. It harnesses Oxford’s world-leading cancer research with the core aim of facilitating collaboration to ensure rapid translation from scientific discovery to treatments for patients.

Cancer Research UK, Experimental Cancer Medicine Centre Southampton

Southampton is a national centre of excellent in lymphoma and melanoma care research, with specialist clinical services in all other major cancer types.  The ECMC provides the specialist laboratory, administarive and clinical delivery support needed to deliver early phase studies quickly and fully.

The Centre aims to build upon its expertise in immunotherapy, uniting both laboratory and clinical research teams to develop novel treatments for both solid and haematological cancers.

Southampton has medical imaging, cellular therapy and radiopharmacy facilities and hosts a fully Human Tissue Association (HTA) accredited tissue bank.

University of Glasgow

Founded in 1451, The University of Glasgow is the fourth oldest university in the English-speaking world. It is a major research-led university operating in an international context, currently a member of Universitas 21, the international network of research universities, and the Russell Group.